A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Nov 16, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q3 FY2026, filed Nov 9, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the TTRX SEC filings page.
This page shows Turn Therapeutics Inc. (TTRX) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 2 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Turn Therapeutics expanded its balance sheet mainly through financing, while operating spending still produced losses and cash outflows.
The 2025 balance-sheet repair came from financing rather than operations: financing cash flow was$6.9M versus operating cash flow of-$2.6M . Equity turned positive, but reported returns remained negative, indicating that the stronger balance sheet does not yet reflect profitable operations.
The expense mix changed sharply: SG&A rose
Short-term liquidity tightened from a 1.6x current ratio in FY2024 to 0.9x in FY2025, even as current assets reached
Financial Health Signals
We do not publish a peer-relative financial health score for Turn Therapeutics Inc., because the score only covers companies whose filings and listing give us what it needs to compare them with their peers. The signals and metrics below are current.
Turn Therapeutics Inc. passes 2 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 2 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).
Turn Therapeutics Inc. reported a net loss of $3.2M while operations used $2.6M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
Turn Therapeutics Inc. reported a net loss of $6.2M in Q3 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Turn Therapeutics Inc. earned -$0.21 per diluted share (EPS) in Q3 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Not reported for Q3 2026.
Not reported for Q3 2026.
Cash & Balance Sheet
Turn Therapeutics Inc. held $9.4M in cash against $5.7M in long-term debt as of Q3 2026.
Not reported for Q3 2026.
Not reported for Q3 2026.
Margins & Returns
Turn Therapeutics Inc.'s quarterly ROE was -109.5% in Q3 2026: one quarter's net income over shareholder equity, not annualized. This is up 268.3 percentage points from the same quarter a year earlier. Against the prior quarter it is up 742.2 percentage points.
Not reported for Q3 2026.
Not reported for Q3 2026.
Not reported for Q3 2026.
Capital Allocation
Turn Therapeutics Inc. invested $605K in research and development in Q3 2026. This represents an increase of 281.3% from the same quarter a year earlier. Against the prior quarter it is up 27.4%.
Not reported for Q3 2026.
Not reported for Q3 2026.
TTRX Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| R&D Expenses | $605K+281.3% | $475K+657.9% | $109K+1081.9% | $35K | $159K+3.5% | $63K | $9K | N/A |
| SG&A Expenses | $1.4M-21.4% | $1.2M-11.6% | $1.1M+202.5% | $2.2M | $1.8M+237.7% | $1.3M | $376K | N/A |
| Operating Income | -$2.0Mn/m | -$1.6Mn/m | -$1.2Mn/m | -$2.2M | -$1.9Mn/m | -$1.4M | -$385K | N/A |
| Interest Expense | $0 | $241K | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income | -$6.2Mn/m | -$5.8Mn/m | -$971Kn/m | $279K | -$1.9Mn/m | -$1.2M | -$329K | N/A |
| EPS (Basic) | -$0.21n/m | -$0.20n/m | -$0.03n/m | $0.01n/m | -$0.07n/m | -$0.05 | -$0.01 | -$0.02 |
| EPS (Diluted) | -$0.21n/m | -$0.20n/m | -$0.03n/m | $0.01n/m | -$0.07n/m | -$0.05 | -$0.01 | -$0.02 |
| Diluted Shares (Avg) | 30M+7.7% | 30M+8.3% | 29M+9.3% | N/A | 28M+5.0% | 27M | 27M | N/A |
Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, EBITDA, Income Tax.
TTRX Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $16.3M+280.4% | $17.0M | $18.6M | $12.2M+493.6% | $4.3M | N/A | N/A | $2.0M |
| Current Assets | $11.1M+236.3% | $10.4M | $11.5M | $5.2M+373.3% | $3.3M | N/A | N/A | $1.1M |
| Cash & Equivalents | $9.4M+1736.3% | $9.9M+211.9% | $11.0M+600.1% | $4.0M+708.3% | $514K+3.1% | $3.2M | $1.6M | $498K |
| Short-Term Investments | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0 | $0 | $0 |
| Long-Term Investments | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0 | $0 | $0 |
| Total Liabilities | $10.7M+180.9% | $16.3M | $12.5M | $7.5M+235.8% | $3.8M | N/A | N/A | $2.2M |
| Current Liabilities | $3.5M+50.6% | $8.8M | $5.1M | $6.0M+748.0% | $2.3M | N/A | N/A | $708K |
| Non-Current Liabilities | $7.2M+383.6% | $7.5M | $7.4M | $1.5M-3.0% | $1.5M | N/A | N/A | $1.5M |
| Long-Term Debt | $5.7M | $6.1M | $5.9M | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $5.7M+1029.4% | $687K-61.3% | $6.1M+647.2% | $4.7Mn/m | $504Kn/m | $1.8M | $819K | -$177K |
| Retained Earnings | -$35.4Mn/m | -$29.2M | -$23.4M | -$22.4Mn/m | -$22.7M | N/A | N/A | -$19.2M |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill.
TTRX Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$1.5Mn/m | -$923Kn/m | -$1.6Mn/m | -$1.2Mn/m | -$589K | -$500K | -$298K | -$431K |
| Stock-Based Compensation | N/A | N/A | $281K+266.6% | N/A | N/A | N/A | $77K | N/A |
| Investing Cash Flow | -$16Kn/m | -$6K | -$12K | -$31Kn/m | -$90K | N/A | N/A | -$8K |
| Financing Cash Flow | $1.6M+176.0% | $1-100.0% | $7.8M+680.1% | $3.2M+508.5% | $595K | $2.1M | $998K | $522K |
Not reported in any period shown, so not listed: Depreciation & Amortization, Capital Expenditures, Free Cash Flow, Dividends Paid, Share Buybacks.
TTRX Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| Return on Equity | -109.5%+268.3pp | -851.7%-781.8pp | -15.9%+24.3pp | 5.9% | -377.8% | -69.9% | -40.1% | N/A |
| Return on Assets | -38.1%+6.2pp | -34.5% | -5.2% | 2.3% | -44.3% | N/A | N/A | N/A |
| Current Ratio | 3.19+1.8x | 1.19 | 2.23 | 0.87-0.7x | 1.43 | N/A | N/A | 1.55 |
| Debt-to-Equity | 1.01 | 8.83 | 0.97 | N/A | N/A | N/A | N/A | N/A |
| Liabilities-to-Equity | 1.87-5.7x | 23.69 | 2.05 | 1.60 | 7.53 | N/A | N/A | N/A |
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Asset Turnover, FCF Margin.
Note: The current ratio is below 1.0 (0.87), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it. Market cap is stated at each company's latest close.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Turn Therapeutics Inc. TTRX | FY2025 | N/A | -$3.2M | N/A | $261.4M | — |
| Century Therapeutics, Inc. IPSC | FY2025 | $109.2M | -$9.6M | -8.8% | $297.8M | 60/100 |
| Allogene Therapeutics, Inc. ALLO | FY2025 | $0 | -$190.9M | N/A | $279.6M | — |
| Ocugen, Inc. OCGN | FY2025 | $4.4M | -$67.8M | N/A | $262.3M | 43/100 |
| Nautilus Biotechnolgy, Inc. NAUT | FY2025 | N/A | -$59.0M | N/A | $267.5M | — |
| Inovio Pharmaceuticals, Inc. INO | FY2025 | $65K | -$84.9M | N/A | $262.2M | — |
Where Turn Therapeutics Inc. Ranks
Frequently Asked Questions
No, Turn Therapeutics Inc. (TTRX) reported a net loss of $12.8M over the trailing 12 months to September 30, 2026. In fiscal year 2025 it reported a net loss of $3.2M.
Turn Therapeutics Inc. (TTRX) had EBITDA of -$5.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
Turn Therapeutics Inc. (TTRX) has a return on equity of -68.2% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
Turn Therapeutics Inc. (TTRX) recorded an outflow of $2.6M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
Turn Therapeutics Inc. (TTRX) had $12.2M in total assets as of fiscal year 2025, including both current and long-term assets.
Turn Therapeutics Inc. (TTRX) invested $266K in research and development during fiscal year 2025.
Turn Therapeutics Inc. (TTRX) had a current ratio of 0.87 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.
Turn Therapeutics Inc. (TTRX) had a liabilities-to-equity ratio of 1.60 as of fiscal year 2025, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity. No debt-to-equity ratio is shown for fiscal year 2025, because the filing data we hold for that year carries no long-term debt figure.
Turn Therapeutics Inc. (TTRX) had a return on assets of -26.3% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
Turn Therapeutics Inc. (TTRX) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to September 30, 2026). The market capitalization is $261.4M as of Nov 16, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
Turn Therapeutics Inc. (TTRX) has no price-to-sales ratio at the moment: no revenue reported. The market capitalization is $261.4M as of Nov 16, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
At the end of fiscal year 2025, Turn Therapeutics Inc. (TTRX) held $4.0M in cash, cash equivalents and investments, and reported an operating cash outflow of $2.6M over that year. Dividing the one by the other, the reported balance equals about 19 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
Turn Therapeutics Inc. (TTRX) has a Piotroski F-Score of 2 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Turn Therapeutics Inc. (TTRX) reported a net loss of $3.2M while operations used $2.6M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.